Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Parsa ArmanDepartment of Pharmacology & Toxicology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.ORCID 0009-0000-3787-5474
Zahra HaghighijooDepartment of Pharmacology & Toxicology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.ORCID 0000-0001-5119-1028
Carmen A LupascuInstitute of Biophysics, National Research Council, 90146 Palermo, Italy.
Aditya K SinghDepartment of Pharmacology & Toxicology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.ORCID 0000-0001-7549-8163
Nana A GoodeDepartment of Pharmacology & Toxicology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.
Timothy J BaumgartnerDepartment of Pharmacology & Toxicology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.ORCID 0000-0002-0330-577X
Jully SinghDepartment of Pharmacology & Toxicology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.
Yu XueDepartment of Pharmacology & Toxicology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.ORCID 0009-0001-6625-704X
Pingyuan WangDepartment of Pharmacology & Toxicology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.ORCID 0009-0005-0368-5070
Haiying ChenDepartment of Pharmacology & Toxicology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.
Dinler A AntunesDepartment of Biology and Biochemistry, University of Houston, Houston, TX 77004, USA.ORCID 0000-0001-7947-6455
Marijn LijffijtIonTX Inc., Friendswood, TX 77546, USA.
Jia ZhouDepartment of Pharmacology & Toxicology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.ORCID 0000-0002-2811-1090
Michele MiglioreInstitute of Biophysics, National Research Council, 90146 Palermo, Italy.
Fernanda LaezzaDepartment of Pharmacology & Toxicology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.ORCID 0000-0003-1141-1852
Funding
Probing brain circuit and behavior with protein:protein interaction modulatorsR01MH132226 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Fernanda Laezza, Jia Zhou · 2023 to 2026
$3.2M
Neurotrophin-dependent regulation of voltage-gated sodium channelsR01MH124351 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI LAEZZA, FERNANDA · 2020 to 2024
$3.0M
Neurotoxicology of deltamethrin in the developing brainR01ES031823 · NIEHS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GREEN, THOMAS ARTHUR, LAEZZA, FERNANDA · 2020 to 2024
$2.8M
Discovery of Chemical Probes for Psychiatric Disorders and AddictionR01MH111107 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI LAEZZA, FERNANDA, ZHOU, JIA · 2016 to 2018
$1.6M
High-Throughput Automated Patch Clamp SystemS10OD032293 · OD · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SPUDICH, JOHN LEE · 2022 to 2022
$599k
Advancing FGF13-Nav1.6 modulators to normalize Nucleus Accumbens activity for Cocaine Use DisorderR43DA063261 · NIDA · IONTX INC. · PI LIJFFIJT, MARIJN · 2025 to 2025
$400k
FGF13: a novel druggable target for treating substance abuse disordersU18DA052504 · NIDA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI LAEZZA, FERNANDA · 2020 to 2020
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
FGF14 Peptide Derivative Differentially Regulates Nav1.2 and Na · full record | OpenQuestion